King Pharmaceuticals®, Inc. 2Q Profit Plunges 53% on Generic Skelaxin Sales
Forbes -- Pain drug maker King Pharmaceuticals Inc. said Monday its profit dropped 53 percent in the second quarter as generic competition eroded sales of its muscle relaxant Skelaxin.